The Indian government has amended the Drugs Rules, 1945, to bring cell or stem cell derived products, gene therapeutic products, and xenografts under the Centrally Licence Approving Authority (CLAA) framework. This move significantly tightens regulatory oversight for advanced medical technologies, aligning India's rules with global best practices.
Scope of the Amendment
Under the Drugs and Cosmetics Act, certain critical drugs and biological products already face joint supervision by central and state regulators. These include vaccines and recombinant DNA-based medicines. The latest amendment expands this list to include emerging technologies such as stem cell-based regenerative treatments, CAR-T cell therapies, gene replacement and gene editing products, and xenografts — animal tissue-derived products like heart valves used in transplants.
According to the Health Ministry, the inclusion of these products under the CLAA framework will facilitate a system of joint oversight by central and state licensing authorities, ensuring uniform regulatory standards across the country. The amendment aims to increase regulatory rigour for these complex, rapidly evolving medical fields.
Why Enhanced Scrutiny is Needed
Cell- or stem cell-derived products are increasingly used to treat blood cancers such as leukemias and lymphomas. Gene therapeutic products address genetic disorders and various cancers. Xenografts find application in cardiology and orthopedics. Because these technologies are highly specialized and rapidly advancing, they require enhanced regulatory scrutiny to ensure patient safety, the government stated.
The CLAA framework already oversees the import of all medical devices, authorizes clinical trials, and approves the manufacture of high-risk products. By bringing these new categories under the same umbrella, the government aims to reinforce India's regulatory framework in step with scientific progress.
Impact on Industry and Patients
Industry experts believe the amendment will create a more predictable and rigorous approval process, potentially boosting confidence among investors and manufacturers. For patients, it promises safer access to cutting-edge therapies. The move also positions India among countries with robust oversight for advanced therapies, similar to regulations in the US and EU.
The amendment was notified in the Gazette of India and will take effect immediately. The Health Ministry has indicated that further guidelines for manufacturers and researchers will be issued soon to facilitate compliance.
